'For quarter ending June 2024, consolidated Net sales (including other operating income) of Cipla has increased 5.77% to Rs 6693.94 crore compared to quarter ended June 2023. Sales of Phamaceuticals segment has gone up 5.99% to Rs 6,389.30 crore (accounting for 94.75% of total sales). Sales of New Ventures segment has gone down 0.13% to Rs 353.98 crore (accounting for 5.25% of total sales). Inter-segment sales came down from Rs 54.04 crore to Rs 49.34 crore.
Profit before interest, tax and other unallocable items (PBIT) has jumped 17.13% to Rs 1,629.31 crore. PBIT of Phamaceuticals segment rose 18.01% to Rs 1,630.64 crore (accounting for 100.08% of total PBIT). PBIT of New Ventures reported loss of Rs 1.33 crore compared to profit of Rs 9.19 crore.
PBIT margin of Phamaceuticals segment rose from 22.92% to 25.52%. PBIT margin of New Ventures segment fell from 2.59% to 0.38%. &nbs...
Pleaselogin & subscribe to view the full report.
More Reports
-
(22-Jan-2025)
Dalmia Bharat
PAT down 76.8% YoY to Rs 61 crore in Q3FY2025
-
Revenue up 16.05% YoY to Rs 354.3 crore in Q3FY2025
-
AUM growth, asset quality and margin improves
-
(22-Jan-2025)
L&T Finance
Retail loan growth healthy at 23%, rural business segment shows high slippages
|
|